BCTX

Nov 03, 9:36 AMBriaCell announces four new Bria-OTS+ and CD80 immunotherapy preclinical data presentations for SITC 2026 meeting

Peers: GLSI ELTX SLS ATOS PDSB IMMP IMNN MAIA AIM GOVX

Scroll to Statements

Index	-
Market Cap	28.13M
Enterprise Value	6.75M
Income	-34.90M
Sales	0.00M
Book/sh	1.88
Cash/sh	2.35
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	31
IPO	Oct 28, 2010

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.71
P/C	1.37
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.76
Current Ratio	2.76
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-9.33
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	67.06% 56.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	87.83%
Sales Y/Y TTM	-
EPS Q/Q	67.06%
Sales Q/Q	-
Earnings	Jun 10 BMO
EPS/Sales Surpr.	- -

Insider Own	0.15%
Insider Trans	0.00%
Inst Own	13.81%
Inst Trans	1.47%
ROA	-154.34%
ROE	-203.63%
ROIC	-212.82%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-6.67%
SMA50	-13.18%
SMA200	-14.96%
Trades

Shs Outstand	8.73M
Shs Float	8.72M
Short Float	9.05%
Short Ratio	3.02
Short Interest	0.79M
52W High	13.09 -75.38%
52W Low	2.60 23.94%
Volatility	8.86% 6.53%
ATR (14)	0.23
RSI (14)	40.43
Beta	1.31
Rel Volume	0.01
Avg Volume	261.32K
Volume	195

Perf Week	-2.64%
Perf Month	-19.44%
Perf Quarter	-11.47%
Perf Half Y	-21.40%
Perf YTD	-54.68%
Perf Year	-68.47%
Perf 3Y	-99.50%
Perf 5Y	-99.79%
Perf 10Y	-99.95%
Recom	1.00
Target Price	150.00
Prev Close	3.19
Price	3.22
Change %	1.02%

Consensus

Strong Buy

Avg. Price Target

$150.00

Implied Upside

+4,554.8%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Feb 14, 2022	Initiated	HH.C. Wainwright	Buy	$25	+675.8%

Nov-03-26 09:00AM	BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 (GlobeNewswire)
Oct-23-26 07:30AM	BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer (GlobeNewswire)
Oct-06-26 07:30AM	BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting (GlobeNewswire)
Sep-14-26 07:30AM	Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study (GlobeNewswire)
Sep-08-26 07:30AM	BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center (GlobeNewswire)
08:47AM	Loading…
Aug-24-26 08:47AM	BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone (InvestorsHub) -14.99%
07:30AM	BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+ (GlobeNewswire)
Aug-05-26 07:30AM	BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer (GlobeNewswire)
Jul-16-26 07:30AM	BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer (GlobeNewswire)
Jul-15-26 07:30AM	BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT (GlobeNewswire) +6.49%
Jul-07-26 07:30AM	BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT (GlobeNewswire)
Jun-25-26 07:30AM	BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT (GlobeNewswire)
Jun-02-26 04:05PM	BriaCell Therapeutics Announces Closing of Offering (GlobeNewswire)
Jun-01-26 07:30AM	BriaCell Presents Positive Clinical Data at ASCO 2026 (GlobeNewswire) -9.07%
May-31-26 07:59PM	BriaCell Therapeutics Announces Pricing of Offering (GlobeNewswire)
07:30AM	Loading…
May-26-26 07:30AM	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
May-22-26 07:30AM	BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026 (GlobeNewswire) -6.18%
May-15-26 07:30AM	BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ (GlobeNewswire) -25.43%
May-14-26 07:30AM	BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer (GlobeNewswire)
May-13-26 07:30AM	BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study (GlobeNewswire)
May-12-26 07:30AM	BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients (GlobeNewswire)
May-07-26 07:30AM	BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study (GlobeNewswire)
May-06-26 07:30AM	BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer (GlobeNewswire)
Apr-27-26 07:30AM	BriaCell Announces Six Clinical Data Presentations at ASCO 2026 (GlobeNewswire)
Apr-21-26 07:30AM	BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ in Preclinical Cancer Models (GlobeNewswire)
Apr-20-26 07:30AM	BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting (GlobeNewswire) -9.26%
Mar-31-26 04:05PM	BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License (GlobeNewswire)
Mar-18-26 07:30AM	BriaCell to Present Positive Clinical Data for Bria-IMT and Preclinical Data for Next Generation Bria-OTS+ Personalized Immunotherapy at the 2026 AACR Conference (GlobeNewswire) -5.27%
Mar-10-26 07:30AM	BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting (GlobeNewswire)
Mar-05-26 04:04PM	BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting (GlobeNewswire)
05:30PM	Loading…
Feb-18-26 05:30PM	BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License (GlobeNewswire)
Feb-17-26 07:30AM	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Jan-28-26 07:30AM	BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation (GlobeNewswire)
Jan-27-26 07:30AM	BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients (GlobeNewswire) +5.62%
Jan-15-26 04:05PM	BriaCell Therapeutics Announces Closing of US$30 million Public Offering (GlobeNewswire) -7.61%
Jan-14-26 06:36AM	What's Going On With BriaCell Therapeutics Stock Wednesday? (Benzinga) -55.49%
Jan-13-26 09:00PM	BriaCell Therapeutics Announces Pricing of $30 million Public Offering (GlobeNewswire) +42.93%
07:30AM	BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS Patient (GlobeNewswire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
Dec-18-25 07:30AM	"Eleven clinical trials that will shape medicine in 2026" - BriaCell Phase 3 Trial Featured in Nature Medicine (GlobeNewswire)
Dec-10-25 07:30AM	BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS 2025 (GlobeNewswire) -7.90%
Dec-09-25 07:30AM	BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout (GlobeNewswire)
Dec-02-25 07:30AM	BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS 2025 (GlobeNewswire)
Nov-25-25 07:30AM	BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS 2025 (GlobeNewswire) +13.53%
Nov-20-25 07:30AM	BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics (GlobeNewswire)
Nov-18-25 07:30AM	BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS 2025 (GlobeNewswire)
Nov-07-25 07:30AM	BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+ at SITC 2025 (GlobeNewswire) +15.06%
Nov-04-25 07:30AM	BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+ in Breast and Prostate Cancer Models (GlobeNewswire)
Oct-28-25 04:01AM	Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding (Zacks)
Oct-27-25 03:05PM	Top 3 Earnings Acceleration Buys for November (Zacks)
Oct-22-25 07:30AM	BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire) -5.64%
Oct-21-25 07:50AM	BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study (GlobeNewswire) +5.19%
07:30AM	BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+ for Breast Cancer (GlobeNewswire)
Oct-20-25 07:30AM	BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025 (GlobeNewswire)
Oct-13-25 07:30AM	BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025 (GlobeNewswire) -8.99%
Oct-03-25 07:30AM	BriaCell to Present Bria-OTS+ Preclinical Data at SITC 2025 Annual Meeting (GlobeNewswire)
Sep-12-25 12:00PM	All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy (Zacks)
Aug-26-25 07:30AM	BriaCell's Bria-OTS+ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal (GlobeNewswire) +9.61%
Aug-25-25 07:30AM	BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+ in Prostate Cancer (GlobeNewswire) +7.32%
Aug-21-25 12:00PM	BriaCell Announces Proposed Effective Date of Share Consolidation (GlobeNewswire) -5.13%
Aug-13-25 07:30AM	BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer (GlobeNewswire)
Aug-05-25 08:17PM	BriaCell Announces Proposed Effective Date of Share Consolidation (GlobeNewswire) -19.00%
Jul-31-25 07:30AM	BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study (GlobeNewswire) -7.15%
Jul-30-25 07:30AM	BriaCell Awarded New Zealand Patent for its Whole Cell Technology (GlobeNewswire)
Jul-29-25 07:30AM	BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents (GlobeNewswire)
Jul-25-25 07:30AM	BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025 (GlobeNewswire)
Jul-16-25 04:05PM	BriaCell Therapeutics Announces Closing of $15 million Public Offering (GlobeNewswire) +6.49%
Jul-15-25 03:40PM	Canadian Investment Regulatory Organization Trade Resumption - BCT (PR Newswire) -61.78%
03:30PM	Canadian Investment Regulatory Organization Trading Halt - BCT (PR Newswire)
03:05PM	BriaCell Therapeutics Announces Pricing of $15 million Public Offering (GlobeNewswire)
07:30AM	BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Jul-11-25 07:30AM	BriaCell's Bria-IMT Demonstrates Survival Advantage over Trodelvy and Control Group in Metastatic Breast Cancer (GlobeNewswire)
Jul-10-25 07:30AM	BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer Patient (GlobeNewswire)
Jul-09-25 07:30AM	BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS Metastatic Breast Cancer Study (GlobeNewswire) -27.49%
Jul-08-25 07:30AM	BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer (GlobeNewswire)
Jul-02-25 07:30AM	BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven (GlobeNewswire)
Jun-24-25 07:30AM	BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Jun-04-25 07:30AM	BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26 (GlobeNewswire)
Jun-02-25 07:30AM	BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025 (GlobeNewswire)
May-27-25 07:30AM	BriaCell Bria-OTS Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor (GlobeNewswire)
May-23-25 07:30AM	BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025 (GlobeNewswire) -9.97%
May-20-25 07:30AM	BriaCell CEO Letter to Shareholders (GlobeNewswire) +11.25%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire) -8.07%
Apr-30-25 07:30AM	BriaCell Reports Late-Breaker Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified (GlobeNewswire)
Apr-28-25 04:05PM	BriaCell Therapeutics Announces Closing of $13.8 million Public Offering (GlobeNewswire) -8.20%
07:30AM	BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+ Development (GlobeNewswire)
Apr-24-25 08:00PM	BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering (GlobeNewswire) +11.05% -13.76%
07:30AM	BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS (GlobeNewswire)
Apr-23-25 07:30AM	BriaCell Announces Four Clinical Data Presentations at ASCO 2025 (GlobeNewswire)
Apr-22-25 07:30AM	BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) (GlobeNewswire) +27.68%
Apr-16-25 07:30AM	BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer (GlobeNewswire) +19.47%
Apr-10-25 08:00AM	BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3 (GlobeNewswire)
Mar-26-25 08:00AM	BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference (GlobeNewswire)
Mar-20-25 08:00AM	Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer (GlobeNewswire)
Feb-05-25 06:15PM	BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting (GlobeNewswire) +9.27% -9.60%
04:05PM	BriaCell Therapeutics Announces Closing of Public Offering (GlobeNewswire)
Feb-03-25 07:59PM	BriaCell Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -18.65%
04:45PM	BriaCell Therapeutics Announces Proposed Public Offering of Common Shares (GlobeNewswire)
07:30AM	BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS (GlobeNewswire)
Jan-27-25 06:42PM	BriaCell Announces Completion of 15:1 Share Consolidation (GlobeNewswire)

Show Previous News

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

M.D.Dr. William V. Williams FCPA

C.A.Mr. Gadi Levin B.Com.

Chief Scientific OfficerDr. Miguel A. Lopez-Lago Ph.D.

M.P.H.Dr. Giuseppe Del Priore M.D.

M.D.Dr. Charles Louis Wiseman FACP

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BriaCell Therapeutics Corp

Upgrade your Finviz experience